ADICET BIO INC (ACET)       19.26  +0.68 (+3.66%)

19.26  +0.68 (+3.66%)

US0070021086 - Common Stock - After market: 18.78 -0.48 (-2.49%)


Fundamental Rating

5

Overall ACET gets a fundamental rating of 5 out of 10. We evaluated ACET against 632 industry peers in the Biotechnology industry. While ACET has a great health rating, its profitability is only average at the moment. ACET is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

5

ACET has a Return On Assets of -15.73%. This is amongst the best returns in the industry. The industry average is -44.83%. ACET outperforms 85% of its industry peers.
ACET has a Profit Margin of -182.97%. This is better than the industry average of -444.43%.

The Piotroski-F score of ACET is 5.00. This is a neutral score and indicates average health and profitability for ACET.
ACET has negative profitability rations, so we won't be analyzing them here.
VS Industry

ROA (-15.73%) VS Industry: 85% outperformed.

-950.38
52.28

Profit Margin (-182.97%) VS Industry: 64% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

1

When comparing the current price to the book value of ACET, we can conclude it is valued correctly. It is trading at 2.60 times its book value.
The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.

Also next year ACET is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the price book ratio of ACET to the average industry price book ratio of 1.72, ACET is valued more expensive than its industry peers.
VS Industry

Price/Book (2.6) VS Industry: 35% outperformed.

137.61
0.10

Growth

Growth Rating

6

The Earnings Per Share has grown by an impressive 29.13% over the past year.
ACET shows a strong growth in Revenue. In the last year, the Revenue has grown by 214.88%.

ACET is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 18.52% yearly.
Based on estimates for the next 5 years, ACET will show a small growth in Earnings Per Share. The EPS will grow by 9.39% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 29.13% 36.68% -2.01% -5.57% 9.39%
RevenueN/A N/A 214.88% 325.84% -16.22% 16.93% 18.52%

Health

Health Rating

8

ACET has a Current Ratio of 16.59. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio of ACET is much better than the industry average of 6.16. ACET has a better rating than 87% of its industry peers.
ACET has a Quick Ratio of 16.59. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of ACET is much better than the industry average of 6.05. ACET has a better rating than 87% of its industry peers.

An Altman-Z score of 12.12 indicates that ACET is not in any danger for bankruptcy at the moment.
The Altman-Z score of ACET is much better than the industry average of -0.81. ACET has a better rating than 90% of its industry peers.
The Debt to Equity ratio of ACET is in line with the industry averages.
The Piotroski-F score of ACET is 5.00. This is a neutral score and indicates average health and profitability for ACET.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (16.59) VS Industry: 87% outperformed.

0.02
84.53

Current Ratio (16.59) VS Industry: 87% outperformed.

0.02
85.09

Altman-Z (12.12) VS Industry: 90% outperformed.

-135.10
443.02

Dividend

Dividend Rating

0

ACET does not give a dividend.

ACET Daily chart

ADICET BIO INC19.26

NASDAQ:ACET (12/2/2022, 7:17:38 PM)+0.68 (+3.66%)

After market: 18.78 -0.48 (-2.49%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 03-13 2023-03-13
Ins Owners 0.69% Inst Owners 96.98%
Market Cap 825.32M Analysts 87.06
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 27.1 P/B 2.6
EV/EBITDA -8.96
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 29.13% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -20.45%
EPS Next Y 36.68% EPS Next 2Y -2.01%
EPS Next 3Y -5.57% EPS Next 5Y 9.39%
Revenue growth 1Y 214.88% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q -100%
Revenue Next Year 325.84% Revenue Next 2Y -16.22%
Revenue Next 3Y 16.93% Revenue Next 5Y 18.52%
Health
Current Ratio 16.59 Quick Ratio 16.59
Altman-Z 12.12 F-Score 5
Debt/Equity 0 WACC 8.99%
ROIC/WACC N/A
Profitability
ROA -15.73% ROE N/A
ROICexgc N/A ROIC N/A
PM -182.97% OM -181.65%
Asset Turnover 0.09

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA